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Objective: Managing type 1 diabetes (T1D) requires the ability to make complex and critical
decisions regarding treatment, to execute complex tasks accurately, and to make adjustments
when problems arise. This requires effective neuropsychological competences of patients and
their families, especially in the domain of executive functioning (EF): the ability to self-monitor,
plan, solve problems, and set priorities. Previous research focused mainly on child EF, neglect-
ing the impact of parental EF. This study included both mothers and fathers and examined
associations between child and parental EF and treatment adherence to T1D in a broad age
range of patients.
Methods: Parents of 270 patients (6-18 years) with T1D (mean age 12.7 years; 52.6% female)
were included. Mothers (N = 232) and fathers (N = 168) completed questionnaires on child and
parental EF and on treatment adherence. Analyses examined the associations linking child and
parental EF to treatment adherence and glycemic control (and potential moderation effects in
these associations) using hierarchical linear regression.
Results: Child EF problems were negatively associated with treatment adherence. As an indica-
tion of moderation, this effect was stronger in older children. Better treatment adherence and
glycemic control were reported when both child and parent showed less EF problems. Effects
were more pronounced in mothers than in fathers.
Conclusions: This study demonstrated a significant interplay between child and parental EF in
the association with treatment adherence and glycemic control. Researchers and clinicians
should remain attentive toward the role of neuropsychological concepts such as EF. Implemen-
tation in clinical practice seems meaningful.
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1 | INTRODUCTION
Treatment of type 1 diabetes (T1D) imposes many behavioral
demands on young patients and their families.1 Treatment non-
adherence in children and adolescents is high and is associated with
short- and long-term adverse health outcomes.2–4 Technological
improvements in insulin pumps and continuous glucose monitoring
make treatment more individually tailored and help in managing
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T1D.2,5 However, they also increase the complexity of treatment.
Children’s and families’ disease knowledge and skills for managing the
disease are critical for treatment adherence. Active knowledge
requires an accurate understanding and mastering of the tasks that
are involved in treatment management.6 Patients need to make com-
plex and critical decisions regarding their treatment, execute complex
tasks accurately, and make adjustments when problems arise.6–8
These specific cognitive demands are captured by the multifaceted
construct of executive functioning (EF). EF involves various high-level
self-regulatory cognitive processes related to frontal cortical func-
tions that control and organize lower-order mental processes.7,9 It
includes the facilitation of new ways of behaving and optimization of
one’s approach to unfamiliar circumstances, the ability to self-moni-
tor, focus attention, remember instructions, plan, and use working
memory.7,10,11 Given that higher cortical maturation continues into
adulthood,10,12 the management of T1D might at some point demand
more of children and adolescents than they are cognitively capable
of. Although managing T1D is considered difficult at any age, adoles-
cents especially, are at increased risk for experiencing difficulty
adhering to the treatment regimen and for suboptimal glycemic con-
trol.7,13,14 Research indicates that although cortical maturation
increases in adolescence, EF competencies may decrease due to con-
flicting developmental challenges (eg, more peer-oriented behavior15).
Moreover, whereas young children depend completely on their par-
ents, this dependence increasingly shifts toward shared responsibility
and decision-making in adolescence.16,17
Research on the role of EF in treatment adherence to T1D is
mounting but remains relatively scarce. Neuropsychological studies in
children and adolescents with T1D have established evidence for
weaker cognition compared to healthy controls and even for struc-
tural changes in the brain.18–20 Hence, decreased treatment adher-
ence may be a reflection of impairments in neuropsychological
functioning.8 In terms of EF more specifically, there is research sug-
gesting a bidirectional negative association between EF of children
and adolescents, treatment adherence, and glycemic control.7,21,22
However, results across studies are inconsistent and effect sizes vary
from small to medium. Moreover, parental EF has not been taken into
account and most research on child EF is based upon mother’s and
not father’s report, although there is extensive literature emphasizing
the importance of developmentally appropriate maternal and paternal
involvement in treatment adherence to T1D.23,24
1.1 | This study
As previous studies on EF in children and adolescents with T1D
included mainly mother reports,25 the current multi-informant study
included both parents. Further, previous studies mainly included a
small age range.7 To take into account a developmental perspective,
this study included children and adolescents (6-18 years old), allowing
for examining age as a moderating factor. Finally, as parents play a
significant role in the treatment of their children’s T1D (and especially
so in younger children), this study will investigate parental EF as well.
Three objectives guided this study. (1) To examine the main effects
of child and parental EF problems on treatment adherence and glyce-
mic control (hemoglobin A1c [HbA1c]). We hypothesized that child
and parental EF problems would be associated with poorer treatment
adherence and HbA1c. (2) To examine 3 possible 2-way interaction
effects, that is, whether parental EF problems and child age would act
as moderators in the link between child EF problems and treatment
adherence/glycemic control, and whether child age would act as mod-
erator in the link between parental EF problems and treatment adher-
ence/glycemic control. First, we hypothesized that the negative impact
of child EF problems on treatment adherence may be enhanced or
compensated when parents score either low or high on EF problems.
Second, we hypothesized that the relationship between child EF pro-
blems and treatment adherence might be stronger in older children,
whereas the effect of parental EF problems would be stronger in the
younger age group. (3) To examine the 3-way interaction of child EF
problems, parental EF problems, and child age. We hypothesized that
in the younger age group, the impact of parental EF problems on the
link between child EF problems, treatment adherence, and glycemic
control, would be more pronounced than in the older age group.
2 | METHODS
2.1 | Participants and procedure
Mothers and fathers of children and adolescents with T1D meeting
the following criteria: (1) having a diagnosis of T1D for at least
6 months, (2) aged 6-18 years, and (3) Dutch-speaking, were recruited
from 7 Belgian hospitals. Patients with other severe somatic diagnoses
(eg, cystic fibrosis), cognitive disabilities, and/or other psychiatric diag-
noses known to be related to problems in overall EF (attention deficit
hyperactivity disorder [ADHD] and autism)26 were excluded. Parents
of patients meeting the inclusion criteria were contacted through
e-mail with a link to the online questionnaires using Limesurvey. All
participants signed an online informed consent form. The study was
approved by central and local Institutional Review Boards of all partici-
pating centers and in accordance with the Declaration of Helsinki.
2.2 | Measures
2.2.1 | Demographic and diabetes characteristics
Information on age, sex, ethnicity, educational and professional level,
and family situation was completed by parents. Illness duration and gly-
cemic control in terms of HbA1c value were obtained through chart
review by treating physicians for whom participants gave informed
consent. HbA1c-values closest to the date the parents filled out the
questionnaires (within 3 months before or after questionnaire comple-
tion) were collected. In Belgium, continuity and quality of HbA1c
results are guaranteed as all clinical sites have similar assays to measure
HbA1c. Further, all Belgian laboratories are obliged to participate in an
external quality assessment regarding HbA1c determination.
2.2.2 | EF problems child
The Behavior Rating Inventory of Executive Function-Parent Report
(BRIEF-P27) assesses EF and self-regulation skills in children and ado-
lescents aged 5 to 18 years old through parent reports. Question-
naires contain 86 items and can be divided in 8 non-overlapping
clinical scales (inhibit, shift, emotional control, initiate, working
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memory, plan/organize, organization of materials, and monitor) from
which 2 broader indexes (behavioral regulation and metacognition)
and a global executive composite score can be derived. Answers in
terms of “never,” “sometimes,” or “often” indicate problems in the dif-
ferent areas described over the last 6 months. Higher scores indicate
worse EF. In this study, total composite scores indicating global EF
were used. Reliabilities of the global EF were high in both mother
and father report: α = .97.
2.2.3 | EF problems parent
The Behavior Rating Inventory of Executive Function-Adult (BRIEF-
A28) is a self-report questionnaire assessing EF and self-regulation
capacities in adults from 18 to 90 years of age. It consists of 75 items
and, similarly to the BRIEF-P, can be divided in 9 clinical scales and
2 broader indexes. Reliabilities of the global executive composite
score were high: α = .95 and α = .96 (mother and father report).
2.2.4 | Treatment adherence
The Diabetes Self-Management Profile-Self-Report (DSMP-SR29) is a
24-item measure quantifying self-management behaviors over the past
3 months as reported upon by parents. It was translated in Dutch using
the back-translation procedure. Items are rated on 2, 3, or 4 point Likert
response scales. Total adherence scores were calculated ranging from
0 to 86 with higher scores indicating better treatment adherence. Reli-
abilities were adequate: α = .70 and α = .67 (mother and father report).
2.3 | Statistical analyses
Statistical analyses were performed using SPSS v.24. Four sets of
hierarchical regression analyses were conducted to examine the con-
tribution of EF problems child, EF problems parent, and age—and
their interactions—in the prediction of mother and father reports of
treatment adherence and HbA1c.
All independent variables except for gender (0 = female; 1 = male)
were standardized.30 In step 1, we added gender, age, and illness dura-
tion. In step 2, main effects of child and parental EF problems were
added. In step 3, 3 2-way interaction terms were added: EF problems
child × EF problems parent, EF problems child × age child, and EF pro-
blems parent × age child. Finally, in step 4, the 3-way interaction was
added: EF problems child × EF problems parent × age child. In steps
3 and 4, we interpreted individual significant interaction terms if the
chunk test indicated a significant increase in R2.31
3 | RESULTS
3.1 | Patient characteristics
Parents of 766 patients meeting the inclusion criteria were contacted
through e-mail. Of 270 (35.2%) patients at least one parent completed
the questionnaires: 232 mothers and 168 fathers. Of 116 patients
both mother and father completed all the questionnaires. About half
of the patients were female (N = 142; 52.6%) and patients were
12.70 years old on average (SD = 3.27). Mean HbA1c was 7.32
(SD = 0.98); median = 7.30 ([6.7;7.9]; 56 mmol/mol). Mean illness
duration was 5.46 years (SD = 3.61). The minority of patients
administered insulin by pump therapy (25.4%). For additional partici-
pants’ characteristics, see Table 1.
3.2 | Correlation analyses
Table 2 displays Pearson correlations among the study variables. A
significant negative correlation was found between child as well as
parental EF problems and treatment adherence within respondents
(ie, same parent reporting on both variables). A consistent significant
positive correlation was also found between mother and father
reports of EF problems child, EF problems parent, and treatment
adherence. Better treatment adherence was correlated with lower
HbA1c, younger age, and longer illness duration.
3.3 | Regression analyses
Standardized betas and R2-values for mother and father reports are
presented in Tables 3 and 4. Figure 1 shows graphical depictions of
all significant 2-way and 3-way interactions.
3.3.1 | Mother reports
In step 1, gender was not significantly related to treatment adherence
or HbA1c, indicating that there were no differences between girls
and boys with regard to treatment adherence and HbA1c. Age and ill-
ness duration were negatively related to treatment adherence and
positively to HbA1c. In step 2, EF problems child was significantly
negatively related to mother reports of treatment adherence and pos-
itively to HbA1c. On the contrary, maternal EF problems were not
related to treatment adherence and HbA1c. In step 3, 3 2-way inter-
actions were examined. First, the 2-way interaction between EF pro-
blems child and EF problems parent reached significance for mother
and father reports of treatment adherence and marginal significance
for HbA1c (P < .10). As displayed in Figure 1A,B, the highest level of
treatment adherence was reached when the child as well as the
mother experienced less problems in EF. Second, the 2-way interac-
tion between child EF problems and age also reached significance for
(mother but not father report of ) treatment adherence and HbA1c.
Hence, as displayed in Figure 1C,D, EF problems child were related
TABLE 1 Participants’ characteristics
Patients
(n = 270)
Mothers
(n = 232)
Fathers
(n = 168)
Age 12.70 (3.27) 43.12 (4.74) 45.01 (5.49)
HbA1c (%) 7.32 (0.98)
Illness duration 5.46 (3.61)
Pump therapy 25.4
Intact family 88.5 83.2 84.4
Belgian nationality 95.6 93.53 89.29
Education
University or college 66.67 63.58
Secondary education 32.9 35.81
Primary education 0.43 0.61
Working 88.31 95.67
Abbreviation: HbA1c, hemoglobin A1c.
Data represent mean (SD) or %.
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to treatment adherence and HbA1c especially in older children: the
worst treatment adherence was reached in older children experien-
cing problems in EF. Third, the 2-way interaction between EF pro-
blems parent and age did not reach significance (unless for a
marginally significant interaction in the link with HbA1c, P < .10). In
step 4, the 3-way interaction effect EF problems child × EF problems
parent × age was significant for HbA1c and marginally significant
(P < .10) for father reports of treatment adherence. Hence, as dis-
played in Figure 1D, the highest levels of HbA1c were attained in
older children manifesting more EF problems, and mothers manifest-
ing less problems in the EF domain.
3.3.2 | Father reports
In step 1, gender and age were not significantly related to treatment
adherence or HbA1c whereas illness duration was negatively related
to treatment adherence and positively to HbA1c. In step 2, EF pro-
blems child were not significantly related to treatment adherence and
marginally significantly to HbA1c (P < .10). The main effect of paternal
EF problems also did not explain a significant additional proportion of
variance in treatment adherence and HbA1c. In step 3, the 2-way
interaction between EF problems child and paternal EF problems
reached marginal significance (P < .10) with father’s report of treat-
ment adherence as outcome variable. This interaction effect was not
TABLE 2 Intercorrelations, means, and SD for scores on diabetes characteristics, the BRIEF (child and parent), and DSMP-SR
1 2 3 4 5 6 7 8 9 10
1. Gender —
2. Age 0.01 —
3. Illness duration 0.06 0.46** —
4. HbA1c% −0.07 0.26*** 0.22*** —
5. Child EF problems MR 0.11 −0.08 0.07 0.16* —
6. Maternal EF problems −0.10 −0.05 0.07 0.10 0.51** —
7. Treatment adherence MR −0.02 −0.30*** −0.30*** −0.38** −0.31*** −0.15* —
8. Child EF problems FR 0.14 −0.14 0.13 0.16* 0.68*** 0.25** −0.07 —
9. Paternal EF problems −0.11 −0.13 0.07 0.08 0.31** 0.38*** 0.01 0.55*** —
10. Treatment adherence FR 0.02 −0.20** −0.30*** −0.22** −0.12 −0.07 0.44*** −0.21** −0.17* —
M — 12.70 5.46 7.32 113.03 96.94 61.33 110.74 94.07 61.39
SD — 3.27 3.61 0.98 25.55 17.61 8.62 22.19 19.25 8.04
Abbreviations: BRIEF, Behavior Rating Inventory of Executive Function; DSMP-SR, Diabetes Self-Management Profile-Self Report; EF, executive func-
tioning; FR, father report; HbA1c, hemoglobin A1c; MR, mother report.
*P < .05; **P < .01; ***P < .001.
TABLE 3 Standardized beta coefficients from the hierarchical
regression analyses for mother reports
Treatment
adherence MR
Treatment
adherence FR HbA1c
Step 1: controls (R2) 0.12*** 0.06 0.09***
Gender (0 = female;
1 = male)
0.00 0.11 .−07
Age −0.22*** −0.04 0.17**
Illness duration −0.19** −0.20┼ 0.18**
Step 2: main effects
(change R2)
0.11**** 0.02 0.03**
EF problems child −0.35*** −0.14 0.16**
EF problems parent 0.04 0.01 0.01
Step 3: 2-way interactions
(change R2)
0.09*** 0.08* 0.06***
EF problems child ×
EF problems parent
0.28*** 0.27* −0.14┼
EF problems child × age −0.17** 0.11 0.23***
EF problems parent × age 0.05 −0.15 −0.13┼
Step 4: 3-way
interactions (change R2)
0.00 0.03┼ 0.02**
EF problems child ×
EF problems
parent × age
0.03 0.25┼ –0.17**
Abbreviations: EF, executive functioning; FR, father report; HbA1c, hemo-
globin A1c; MR, mother report.
┼P < .10; *P < .05; **P < .01; ***P < .001.
TABLE 4 Standardized beta coefficients from the hierarchical
regression analyses for father reports
Treatment
adherence FR
Treatment
adherence MR HbA1c
Step 1: controls (R2) 0.10*** 0.15*** 0.11***
Gender (0 = female;
1 = male)
0.08 0.05 −0.05
Age −0.09 0.23* 0.13
Illness duration −0.26*** −0.22* 0.25**
Step 2: main effects
(change R2)
0.04** 0.00 0.02
EF problems child −0.12 −0.08 0.17┼
EF problems parent −0.12 0.05 −0.03
Step 3: 2-way interactions
(change R2)
0.03 0.02 0.03
EF problems child ×
EF problems parent
0.17┼ 0.14 −0.08
EF problems child × age 0.03 0.16 0.12
EF problems parent × age −0.08 −0.10 0.00
Step 4: 3-way interactions
(change R2)
0.00 0.00 0.00
EF problems child ×
EF problems
parent × age
−0.01 −0.00 0.06
┼P < .10; *P < .05; **P < .01; ***P < .001.
Abbreviations: EF, executive functioning; FR, father report; HbA1c, hemo-
globin A1c; MR, mother report.
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significant in the link with HbA1c. Further, the remaining interaction
effects of child and paternal EF with age did not reach significance,
nor did the 3-way interaction effect in step 4.
4 | DISCUSSION
This study extends prior work on the role of child EF in treatment
adherence by examining child and parental EF in a broad develop-
mental age range of children and adolescents with T1D and by
including both mothers and fathers as informants. This allowed us to
investigate interactions between child EF, parental EF, and age
toward treatment adherence and glycemic control.
With respect to main effects, EF problems child were consistently
associated with poorer treatment adherence (in mother reports) and
worse HbA1c. This confirms earlier research reporting associations
between child EF and treatment adherence,7 with this study pointing
to more pronounced effects for mother rather than father report of
EF. Further, contrary to expectations, parental EF was not related to
treatment adherence nor HbA1c. Such a lack of unique effects already
suggests the importance of examining interactions with other vari-
ables, such as EF problems child and age, to completely understand
the neuropsychological mechanisms underlying treatment adherence.
Indeed, in line with hypotheses, results pointed to a relatively con-
sistent significant interaction effect between child and parental
EF. This effect was again more prominent in mothers, suggesting that
treatment adherence was highest when both mother and child showed
fewer problems in EF. More specifically, results demonstrated that
maternal EF problems were related to treatment adherence, especially
in combination with less EF problems child. However, contrary to
expectations, maternal EF did not seem to provide a protective or cor-
recting effect on poor child EF functioning. Results therefore empha-
size the importance of examining not only child but also parental EF
and the difference in neuropsychological competencies between the 2.
Further in line with our hypotheses, age was a moderator in the
association between child EF and treatment adherence: more
50
52
54
56
58
60
62
64
66
68
Low EF Problems Child
MR
High EF Problems Child
MR
Low EF Problems Child
MR
High EF Problems Child
MR
T
re
at
m
en
t A
dh
er
en
ce
 M
R
Low EF
Problems
Mother
High EF
Problems
Mother
50
52
54
56
58
60
62
64
66
68
70
Low EF
T
re
at
m
en
t A
dh
er
en
ce
 F
R
problems
mother
High EF
problems
mother
50
52
54
56
58
60
62
64
66
68
70
Low EF Problems Child
MR
High EF Problems Child
MR
Low Age
T
re
at
m
en
t A
dh
er
en
ce
 M
R
High Age
6
7
6.5
8
7.5
8.5
9
Low EF problems child
MR
H
bA
1c
High EF problems child
MR
Low Age
High Age
6
7
6.5
8
7.5
8.5
9
Low EF Problems
Child MR
High EF Problems
Child MR
H
bA
1c
(1) High EF Problems
(4) Low EF Problems
Mother, Low Age
Mother, High Age
(2) High EF Problems
Mother, Low Age
(3) Low EF Problems
Mother, High Age
FIGURE 1 Significant interaction effects
GOETHALS ET AL. 5
problems in the EF domain were associated with worse treatment
adherence, especially in older children and adolescents. As stated in
previous research,32 older children and adolescents increasingly take
over responsibility for self-management activities from their parents,
increasing the importance of their own competencies in
EF. However, again, in this study these effects were only found in
mother reports. Hence, age of the child seems to play a more promi-
nent role in mothers’ than in fathers’ perspectives. Contrary to expec-
tations, however, age did not function as a moderator between
parental EF and treatment adherence. Therefore, age seems to be a
more pronounced factor in the link between children’s own EF and
treatment adherence rather than in the link with parents’ EF.
Finally, when examining the 3-way interactions among child EF,
parental EF, and age, results partially supported our hypothesis: in
older children and adolescents, more problems in the child’s EF
domain as reported upon by mothers were related to worse glycemic
control. Interestingly, when combined with less problems in maternal
EF, glycemic control was even worse. This may point to the fact that
mothers confronted with poor glycemic control and EF problems in
their child, may adjust by sharpening their own EF functions to com-
pensate for their child’s functioning, or, from a different viewpoint, to
a possible negative effect of the difference between child and paren-
tal EF. However, as these results stem from a cross-sectional design,
firm interpretations of directionality of effects cannot be made and
should be examined in future longitudinal research.
Overall, findings suggest the importance of the main effect of EF
of children and the interaction with parental EF when examining treat-
ment adherence. Effects of child EF were more pronounced in the
older age group. Further, effects were more pronounced in mother as
compared to father reports. It could be that mothers, as they are often
more closely involved in daily diabetes self-management tasks,33 mon-
itor their children’s (diabetes-related) behavior more closely, which
might enable them to assess treatment adherence and their children’s
functioning more correctly. However, it should also be noted that
although most effects in fathers were not statistically significant,
β-values were often rather similar to those in mothers (eg, for the
main effect of EF problems child on HbA1c). Therefore, the lack of
effects in fathers may also be due to the lower sample size in fathers,
decreasing the power to obtain significant effects.
4.1 | Limitations and suggestions for future research
This study is characterized by some limitations. First, due to the
cross-sectional design, directional interpretations should be made
with caution. Future research should test longitudinal associations to
allow for a more in-depth understanding of the link between child EF,
parental EF, and treatment adherence in children and adolescents
with T1D. Furthermore, as the development of EF depends upon cor-
tical maturation that continues into emerging adulthood,34 future
research on EF should include this age group transitioning to adult
health care. Second, replication of these results with more targeted
measures might be useful. Using a diabetes-specific measure such as
the Diabetes Related Executive Functioning Scale (DREFS35) may be
valuable. Furthermore, all of the behavioral measures were parent-
reported. Therefore, future research should add more objective
measures of treatment adherence and EF to avoid confounding
within respondents. For instance, assessing EF by means of neuro-
psychological testing may generate a more in-depth picture. Third, in
this study children with psychiatric disorders affecting EF were
excluded (ie, ADHD and autism) as these children often get special
help at school and/or medication to enhance EF and broader func-
tioning. It may be valuable for future research to include this sub-
group as the co-occurrence of T1D with these psychiatric diagnoses
may be additionally challenging for treatment adherence. Finally,
some study characteristics such as the relatively low participation
rate, the demographic characteristics, and the relatively good overall
glycemic control may question the representativeness of the sample
which might constitute a relatively well-functioning sample. Data for
patients who declined participation are not available because of ethi-
cal considerations. However, comparisons with data from the Belgian
Diabetes Registry for patients in the same age range showed that our
sample showed somewhat better glycemic control (7.3% vs 8.1%) and
a somewhat shorter diabetes duration (4.7 vs 5.5 years). As previous
studies (eg, 25) also suggest, future studies may benefit from target-
ing children and families in a broader ethnic and educational range
as well.
4.2 | Clinical implications
Provided that the present findings are replicated longitudinally, trans-
lation into future interventions may be valuable. Introducing develop-
mentally appropriate tips and tricks on core EF competencies (such
as planning, shifting attention, setting priorities, etc.) into the routine
educational sessions on diabetes management might be beneficial.21
Moreover, to identify children at risk for poor treatment adherence
and glycemic control, assessment of EF by means of a generic (ie,
BRIEF27) or diabetes-specific questionnaire (ie, DREFS36) may be use-
ful. When there is a clinically significant indication of EF problems,
targeted referral for more elaborate neuropsychological assessment is
recommended.21,36 Hence, educating diabetes teams on the matter
seems useful. For example, when discussing individual patient-
centered decisions in terms of more complex flexible treatments or
the choice between pump or pen therapy, diabetes teams may take
into account a patient’s level of EF. Further, as results indicate the
combined positive effect of child and parental EF, clinicians should
also be attentive to parental competencies in the EF domain. There-
fore, ideally, parental EF is assessed as well, by means of clinical
assessment in routine family anamnesis or by means of a question-
naire (eg, BRIEF-A28). As most interventions in the care for children
and adolescents with T1D are family-based,37 integrating an addi-
tional focus on the role of neuropsychological functioning in treat-
ment adherence in such clinical interventions might be a targeted
approach. For example, psycho-education on normative developmen-
tal stages of EF in children and adolescents (ie, what to expect and
not) might be valuable in helping parents to have realistic expecta-
tions and thus develop more balanced and developmentally appropri-
ate shared responsibility with their children in self-management. This
might also help parents to detect or acknowledge difficulties in their
child’s or own EF, opening the path for referral to even more targeted
diagnosis or treatment of EF problems.
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